Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
- I. Stratton, A. Adler, R. Holman
- MedicineBMJ : British Medical Journal
- 12 August 2000
In patients with type 2 diabetes the risk of diabetic complications was strongly associated with previous hyperglycaemia, with the lowest risk being in those with HbA1c values in the normal range (<6.0%).
10-year follow-up of intensive glucose control in type 2 diabetes.
- R. Holman, S. Paul, M. A. Bethel, D. Matthews, H. Neil
- MedicineNew England Journal of Medicine
- 9 October 2008
Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
- S. Kahn, S. Haffner, G. Viberti
- MedicineNew England Journal of Medicine
- 7 December 2006
The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
- A. Adler, I. Stratton, R. Holman
- MedicineBMJ : British Medical Journal
- 12 August 2000
In patients with type 2 diabetes the risk of diabetic complications was strongly associated with raised blood pressure, with the lowest risk being in those with systolic blood pressure less than 120 mm Hg.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
- Jennifer B. Green, M. A. Bethel, R. Holman
- MedicineNew England Journal of Medicine
- 15 July 2015
Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events.
Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
Relatively fewer patients with type 2 diabetes develop macroalbuminuria, but in those who do, the death rate exceeds the rate of progression to worse nephropathy, and risk of death from all-causes or cardiovascular disease is high.
Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- R. Holman, A. Bethel, Adrian F. Hernandez
- MedicineNew England Journal of Medicine
- 14 September 2017
Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo.
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
This revision of the consensus algorithm for the medical management of type 2 diabetes focuses on the new classes of medications that now have more clinical data and experience and addresses safety issues surrounding the thiazolidinediones.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
- R. Turner, R. Holman, Grp Ukpds.
- MedicineThe Lancet
- 11 September 1998
Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)
Treatment with diet alone, insulin, sulfonylurea, or metformin is known to improve glycemia in patients with type 2 diabetes mellitus, but which treatment most frequently attains target fasting plasma glucose (FPG) concentration of less than 7.8 mmol/L (140 mg/dL) or glycosylated hemoglobin A1c (HbA1c) below 7% is unknown.
...
...